Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0WBIWE
ADC Name
EGFR-ADC-07 (DAR4)
Synonyms
EGFR ADC 07 (DAR4)
   Click to Show/Hide
Organization
Suzhou Medilink Therapeutics Ltd.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Esophageal cancer [ICD11:2B70]
Investigative
Drug-to-Antibody Ratio
5
Structure
Antibody Name
Cetuximab
  Antibody Info 
Antigen Name
Epidermal growth factor receptor (EGFR)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
EGFR-ADC-07(DAR4) linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
18.17
ng/mL
KYSE-520 cells
Esophageal squamous cell carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 18.17 ng/mL Positive EGFR expression (EGFR +++/++)
Method Description
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model Esophageal squamous cell carcinoma KYSE-520 cells CVCL_1355
References
Ref 1 Bioactive substance conjugate, preparation method therefor and use thereof; 2022-08-18.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.